Smith & Nephew SNATS Inc
$ 30.11
1.41%
07 Aug - close price
- Market Cap 12,616,702,000 USD
- Current Price $ 30.11
- High / Low $ 30.26 / 29.84
- Stock P/E 20.48
- Book Value 2.49
- EPS 1.47
- Next Earning Report -
- Dividend Per Share $0.40
- Dividend Yield 2.64 %
- Next Dividend Date -
- ROA 0.05 %
- ROE 0.12 %
- 52 Week High 37.90
- 52 Week Low 28.56
About
Smith & Nephew plc develops, manufactures, markets and sells medical devices worldwide. The company is headquartered in Watford, the United Kingdom.
Analyst Target Price
$33.96
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-04 | 2026-05-06 | 2026-03-02 | 2025-11-06 | 2025-08-05 | 2025-04-30 | 2025-02-25 | 2024-10-31 | 2024-08-01 | 2024-05-01 | 2024-02-27 | 2023-11-02 |
| Reported EPS | None | 0 | 0.38 | 0 | 0.33 | 0 | 0.23 | 0 | 0.756 | 0 | 1.31 | 0 |
| Estimated EPS | None | 0 | 1.12 | 0 | 1.03 | 0 | 0.97 | 0 | 0.93 | 0 | 0.96 | 0 |
| Surprise | 0 | 0 | -0.74 | 0 | -0.7 | 0 | -0.74 | 0 | -0.174 | 0 | 0.35 | 0 |
| Surprise Percentage | None% | None% | -66.0714% | None% | -67.9612% | None% | -76.2887% | None% | -18.7097% | None% | 36.4583% | None% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Previous Dividend Records
| Nov 2026 | May 2026 | Nov 2025 | May 2025 | Nov 2024 | May 2024 | Nov 2023 | May 2023 | Oct 2022 | May 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Payment Date | 2026-11-06 | 2026-05-27 | 2025-11-07 | 2025-05-28 | 2024-11-08 | 2024-05-22 | 2023-11-01 | 2023-05-17 | 2022-10-26 | 2022-05-11 |
| Amount | $0.312 | $0.482 | $0.3 | $0.462 | $0.288 | $0.462 | $0.288 | $0.462 | $0.288 | $0.462 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SNN
2026-08-07 20:41:39
Smith & Nephew (SNN) is facing pressure due to external factors and gaps in its product portfolio, despite its history of innovation in orthopedics, sports medicine, and wound care markets. The company has shown strength in introducing innovations like Oxinium technology for hip replacements and Regeneten for tendon tissue growth. However, recent earnings reports indicate weakness that could persist, highlighting challenges in the first half of the year.
2026-08-06 09:40:09
JPMorgan downgraded Smith & Nephew PLC to Neutral from Overweight, citing a slowdown in the orthopaedics market and the company's loss of market share in knees and hips. The firm also lowered its price target to GBP12.90 from GBP14.38 and expressed skepticism about the company's revenue guidance. Despite the downgrade, an InvestingPro analysis suggests the stock may be undervalued.
2026-08-05 23:43:45
Smith+Nephew, the official Joint Replacement and Sports Medicine Technology Partner of the Pro Football Hall of Fame, is celebrating mobility, recovery, and football traditions during the 2026 Pro Football Hall of Fame Enshrinement Week in Canton, Ohio. The company will host an interactive booth featuring Pro Football Hall of Famers, live podcasts, and giveaways, and will also present the Hall of Famer Walk. This initiative highlights Smith+Nephew's "Life Unlimited" purpose, connecting it with the perseverance and determination exemplified by football legends.
2026-08-05 20:41:39
Smith+Nephew has lowered its full-year 2026 revenue guidance from 6% to 4% due to a disappointing Q2, with revenue growing only 1.6% and orthopedics experiencing a decline. Despite this, the company is maintaining its profit guidance by implementing additional efficiency savings from its 12-Point Plan. The company is banking on new product launches and stabilization in wound care to drive a stronger second half, though challenges remain in various segments.
2026-08-05 08:43:45
Smith & Nephew (SNN) reported Q2 2026 earnings with underlying revenue growth of 1.6%, below expectations due to softness in U.S. Orthopaedics and Advanced Wound Bioactives. Despite a revised full-year revenue outlook to around 4%, the company maintained its profit and cash flow guidance, supported by increased efficiency savings. Management highlighted strategic efforts to address portfolio gaps in Orthopaedics and scale high-growth platforms to offset market headwinds.
2026-08-04 21:42:05
Smith & Nephew plc has issued earnings guidance for the second half of 2026, projecting a revenue growth rate between 5.0% and 5.5%. This forecast represents an increase in growth compared to the first half of the year. The announcement was made on August 4, 2026.
